• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Chronic administration of nano-sized PAMAM dendrimers in vivo inhibits EGFR-ERK1/2-ROCK signaling pathway and attenuate diabetes-induced vascular remodeling and dysfunction
This study showed chronic in vivo administration of PAMAM dendrimers in an animal model of diabetes inhibited EGFR-ERK1/2-ROCK signaling and improved diabetes-induced vascular remodeling and dysfunction in a dose, generation (G6 > G5) and surface chemistry-dependent manner (cationic> anionic> neutral). Thus, naked PAMAM dendrimers have the propensity to modulate key (e.g. EGFR) cell signaling cascades with associated pharmacological consequences in vivo that are dependent on their physicochemical properties. PAMAMs, alone or in combination with vasculoprotective agents, might therefore have a beneficial role in t...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 5, 2019 Category: Nanotechnology Source Type: research

Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient Down-regulation of variant PTPN22 gene in T lymphocytes
Publication date: Available online 12 November 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Marsha Pellegrino, Francesca Ceccacci, Stefania Petrini, Marco Cappa, Giovanna Mancini, Alessandra FierabracciAbstractIn autoimmune diseases as Type 1 diabetes, the actual treatment that provides the missing hormones is not able, however, to interrupt the underlining immunological mechanism. Importantly, novel immunotherapies are exploited to protect and rescue the remaining hormone producing cells. Among probable targets of immunotherapy, the C1858T mutation in the PTPN22 gene, which encodes for the lymp...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 12, 2018 Category: Nanotechnology Source Type: research